Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of trifluridine/tipiracil in previously treated ER-positive, HER2-negative advanced breast cancer
NL-OMON52884Phase 2Completed
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil in breast cancer, sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Percentage of patients progression-free at 8 weeks. Started Sep 2020; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON52884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52884.